Literature DB >> 1906441

Low doses of TRH in amyotrophic lateral sclerosis and in other neurological diseases.

S Congia1, S Tronci, M Ledda, A Porcella, G Coppola.   

Abstract

30 subjects--23 with amyotrophic lateral sclerosis (ALS), 4 with Charcot-Marie Tooth atrophy, 2 with progressive spinal muscle atrophy and 1 with radiation myelopathy--were given chronic low-dose TRH therapy. The effects of treatment were assessed on the scale of Norris et al. (1974). The outcome of the study, in agreement with some and at variance with other studies, was that TRH induced a statistically significant neurological improvement in 17 of the 23 ALS patients but little or none in the other ALS patients and in patients with other neurological diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906441     DOI: 10.1007/bf02337033

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  14 in total

1.  Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis.

Authors:  M H Brooke; J M Florence; S L Heller; K K Kaiser; D Phillips; A Gruber; D Babcock; J P Miller
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

2.  [Treatment of amyotrophic lateral sclerosis with thyrotropin releasing hormone].

Authors:  G Serratrice; C Desnuelle; A Crevat; C Guelton; A Meyer-Dutour
Journal:  Rev Neurol (Paris)       Date:  1986       Impact factor: 2.607

3.  Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials.

Authors:  H Mitsumoto; E D Salgado; D Negroski; M R Hanson; V D Salanga; J F Wilber; A J Wilbourn; A C Breuer; J Leatherman
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

4.  Antagonism of ethanol narcosis by histidyl-proline diketopiperazine.

Authors:  C Prasad; T Matsui; A Peterkofsky
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

5.  The administration of guanidine in amyotrophic lateral sclerosis.

Authors:  F H Norris; P R Calanchini; R J Fallat; S Panchari; B Jewett
Journal:  Neurology       Date:  1974-08       Impact factor: 9.910

6.  Effect of thyrotropin-releasing hormone on ataxia of spinocerebellar degeneration.

Authors:  I Sobue; H Yamamoto; M Konagaya; M Iida; T Takayanagi
Journal:  Lancet       Date:  1980-02-23       Impact factor: 79.321

Review 7.  Intrathecal thyrotropin-releasing hormone in amyotrophic lateral sclerosis.

Authors:  T L Munsat; J Taft; D Kasdon
Journal:  Neurol Clin       Date:  1987-02       Impact factor: 3.806

8.  Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone.

Authors:  K Imoto; K Saida; K Iwamura; T Saida; H Nishitani
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-12       Impact factor: 10.154

9.  Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone.

Authors:  W K Engel; T Siddique; J T Nicoloff
Journal:  Lancet       Date:  1983-07-09       Impact factor: 79.321

10.  Intrathecal thyrotropin-releasing hormone therapy of amyotrophic lateral sclerosis.

Authors:  T Stober; K Schimrigk; S Dietzsch; T Thielen
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

View more
  1 in total

Review 1.  Are thyrotropin-releasing hormone (TRH) and analog taltirelin viable reversal agents of opioid-induced respiratory depression?

Authors:  Marieke Hyke Algera; Joseph F Cotten; Monique van Velzen; Marieke Niesters; Martijn Boon; Daniel S Shoham; Kaye E Dandrea; Rutger van der Schrier; Albert Dahan
Journal:  Pharmacol Res Perspect       Date:  2022-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.